Enveda

Just a short while ago, our friends at NYSE celebrated our Series C on their trading floor. Thank you, Eric J. Dimise, PhD , Johanna Grossman, PhD and other NYSE colleagues!

We’re thrilled to co-lead the $130M Series C funding round for Enveda, which revolutionizes drug discovery by combining AI, metabolomics, and automated lab workflows to deliver medicines at 4x the industry speed. Enveda’s platform has already resulted in a pipeline of 10 development candidates, addressing major challenges in Immunology & Inflammation, Obesity, Fibrosis, and Neurosensory indications. Operating at the intersection of biology and technology, we’re proud to support Enveda’s vision of decoding life’s chemistry to transform healthcare. With this funding, Enveda will: ?? Advance multiple programs toward clinical milestones in 2025–2026 ?? Invest further in their world-leading AI-driven platform ?? Continue building a pipeline of first-in-class and best-in-class therapeutics Congratulations to Viswa Colluru, PhD and the rest of the Enveda team. We can’t wait to partner with you for many years to come! ?? Christian Scherrer, Ala Alenazi, FPV Ventures, Baillie Gifford, Premji Invest, Lux Capital Sarah McBride at Bloomberg has more: https://lnkd.in/dh_FESZU

We said there would be more... > We’re thrilled to announce $???????? ???? ???????????? ?? ?????????????? led by Kinnevik and FPV Ventures , with participation from Baillie Gifford , Premji Invest , Lux Capital , True Ventures, Dimension and many more new and existing partners. With this new capital, we plan to advance multiple drug candidates through Phase 1/2 clinical trials. In just ?? ?????????? ?????????? ?????????? ?????? ???????? ??????????, we’ve gone from a concept to a ????????????????-?????????? ?????????????? with a deep pipeline of ???? ?????????????????????? ????????????????????. ?? Thanks to the hard work of our team and the power of our platform, we’re delivering drug candidates ???? ???????????? ???????? ???????????????? ??????????????—a testament to our thesis, technology, and team. This marks a significant step forward in our journey to transform the future of drug discovery. A heartfelt thank you to our investors, partners, and, most importantly, our talented team for making this possible. Here’s to the next chapter of growth, discovery, and development! ???? Learn more here: https://lnkd.in/g6M4vXST Read our feature in Bloomberg here: https://lnkd.in/gwZM92F2 #SeriesCFunding #BiotechInnovation #ClinicalStageBiotech #fundrasing #Teamwork

We are thrilled to be featured in Forbes for our clinical trial of ENV-294, the first drug derived from nature advanced using AI. ENV-294 can potentially deliver a convenient oral option for treating moderate-to-severe Atopic Dermatitis, a disease that affects more than 30M people in the US alone. Read more: https://lnkd.in/dsbMBhTx

New edition of our healthcare newsletter InnovationRx just dropped. Here's what's inside: ?? Insilico Medicine just released positive topline results for its generative AI-designed drug aimed at treating idiopathic pulmonary fibrosis. ?? I talked to Viswa Colluru, PhD, CEO of Enveda, which just began its first clinical trial for its drug aimed at treating atopic dermatitis. Enveda uses AI and other tools to find promising molecules from nature that could be refined into drugs. ?? Research findings suggest that certain GLP-1s may be able to treat alcohol abuse. And much more! Check it out. https://lnkd.in/gCG2dh5f

This one is special… > We have advanced our first drug into Phase 1 clinical trials! ENV-294 is a first-in-class small molecule with exciting potential to treat atopic dermatitis (commonly known as eczema) – an underserved and devastating inflammatory condition that impacts more than 30 million people of all ages in the US alone – and other inflammatory conditions.? No one person can make a medicine, and this drug is the culmination of many brilliant and hardworking Envedians. This group of enterprising scientists, technologists, and operators has taken us from an idea to building the world's largest dataset of nature's chemistry, the most advanced AI sequencer for life’s chemical code, a state-of-the-art automated drug discovery lab, and a leading drug development team. Along with our phenomenal partners at Dr. Vince Clinical Research, we are thrilled to take this big step for Enveda and patients worldwide. This is an incredible milestone on our journey, and we are just getting started! Learn more at www.enveda.com & see our see our Press Release: https://lnkd.in/gDiyHKKZ #medicine #chemistry #naturalproducts #pharmaceuticalindustry #ML

We're #hiring a new Sr. Director, Regulatory Affairs in Boulder, Colorado. Apply today or share this post with your network.

Join us tomorrow, Oct 16 at 1:50 PM ET, as Enveda Biosciences' CEO and Founder, Viswa Colluru, PhD, speaks on a virtual panel *"An Integrative AI Mindset"* at Endpoints AI Day 2024.?He will discuss how Enveda integrates AI, metabolomics, and automation to translate nature into new medicines. ? Don’t miss this insightful session where science meets innovation! Register here:?https://lnkd.in/gJ6_48wy ? #AI #DrugDiscovery?

?? Exciting news from Enveda Biosciences! We’ve been recognized as one of LinkedIn's Top Startups in Denver! ?? Since our founding in 2019 and our roots in Boulder, Colorado, we’ve expanded to nearly 250 dedicated team members, many of whom are based right here in our vibrant community. Our mission—translating nature into medicine—drives us every day. This achievement is a testament to the hard work and passion of our diverse team, from medicinal chemists to biologists, AI experts, software engineers, and operations professionals. We’re proud of what we've built together, and we’re just getting started. If you're passionate about making an impact, explore our open positions and join us on this incredible journey! https://lnkd.in/eZGMmxBw https://lnkd.in/gwGEycxN #EnvedaBiosciences #TopStartups #JoinUs #InnovationInMedicine

We’re proud to announce that our Senior Research Data Scientist, Christoph A. Krettler ?? will be judging at the Bio x ML Hackathon, hosted by Lux Capital, EvolutionaryScale, and Enveda Biosciences! ?? Don’t miss this opportunity! Apply today at https://hackathon.bio. Open to participants worldwide. ?? #BioxML #Hackathon #ComputationalBiology